rabbit polyclonal anti stat6  (Proteintech)

Journal: PLOS One

Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

doi: 10.1371/journal.pone.0341313

Figure Lengend Snippet: THP-1 cells were treated under different conditions: PMA (50 ng/ml) alone, or PMA (50 ng/ml) for 24 hours, followed by a medium change and subsequent treatment with IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. After this, the medium was replaced with RPMI 1640 medium without FBS for 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) Morphological features of THP-1 cells under different conditions. Left: untreated THP-1 cells. Middle: PMA (50 ng/ml) for 24 hours. Right: PMA for 24 hours, followed by IL-4 and IL-13 (20 ng/ml) and IL-13 (20 ng/ml) for 48 hours. Scale bar: 50 μm. (B) Relative expression of Arg1 mRNA. (C) Relative expression of Arg1 protein. (D) Concentrations of TNF and IL-10 in the supernatant. (E) Relative mRNA expression of JMJD3 and IRF4. (F) Protein expression of JMJD3, p-STAT6-Y641, and IRF4. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: Arg1, arginase 1; PMA, Phorbol 12-myristate 13-acetate; IL-10, interleukin-10; TNF, tumor necrosis factor; JMJD3, Jumonji domain-containing protein 3; IRF4, interferon regulatory factor 4; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

Article Snippet: AS1517499 (HY-100614, MCE) is a novel and potent STAT6 inhibitor.

Techniques: Expressing

Journal: PLOS One

Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

doi: 10.1371/journal.pone.0341313

Figure Lengend Snippet: THP-1 cells were first treated with PMA for 24 hours. Following this, AS1517499 (1μM) was administered for 30 minutes, and then the cells were treated with IL-4 and IL-13. 48 hours later, the medium was replaced with RPMI 1640 medium without FBS and cells were incubated for an additional 24 hours. Protein and mRNA were then extracted, and the supernatant was collected. (A) The mRNA expression of Arg1. (B) Concentrations of TNF in the supernatant of different groups of macrophages. (C) Concentrations of IL-10 in the supernatant of different groups of macrophages. (D) Expression of IRF4 mRNA. (E) Expression of JMJD3 mRNA. (F) Western blot analysis of JMJD3, p-STAT6, and IRF4 protein expression. The experiments were replicated three times. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. Abbreviations: JMJD3, Jumonji domain-containing protein 3; Arg1, arginase 1; TNF, tumor necrosis factor; IRF4, interferon regulatory factor 4; IL-10, interleukin-10; p-STAT6, phosphorylated signal transducer and activator of transcription 6.

Article Snippet: AS1517499 (HY-100614, MCE) is a novel and potent STAT6 inhibitor.

Techniques: Incubation, Expressing, Western Blot

Journal: PLOS One

Article Title: JMJD3 regulates the M2-like macrophage polarization and promotes the growth of breast cancer cells via STAT6/IRF4 axis

doi: 10.1371/journal.pone.0341313

Figure Lengend Snippet: Schematic illustration of the regulatory mechanism by which JMJD3 influences M2-like macrophage polarization and promotes breast cancer cell growth through the STAT6/IRF4 axis.

Article Snippet: AS1517499 (HY-100614, MCE) is a novel and potent STAT6 inhibitor.

Techniques:

Journal: International Journal of Molecular Medicine

Article Title: Orcinol glucoside ameliorates pulmonary fibrosis by suppressing hyaluronic acid synthesis and macrophage M2 polarization via targeting hyaluronic acid synthase 2

doi: 10.3892/ijmm.2026.5764

Figure Lengend Snippet: HA from myofibroblasts induces macrophage M2 polarization via the CD44/STAT6 axis. (A) RAW264.7 macrophages were stimulated with HA for 24 h, and flow cytometry was performed to assess the expression of CD206 (FITC) and CD86 (PE) (n=3 for each group). (B) The content of TGF-β1 in macrophages following HA treatment over 48 h was quantified using ELISA (n=3 for each group). (C) Western blotting analysis of p-STAT6 and total STAT6 expression at various time points following 100 μ g/ml HA stimulation (n=4 for each group). (D) Flow cytometric analysis of CD86 and CD206 expression in macrophages after 24-h treatment with 100 μ g/ml HA and CD44 inhibitor at indicated concentrations (n=3 for each group). (E) TGF-β1 quantification by ELISA in culture supernatants (n=3 for each group). (F) Western blotting analysis of p-STAT6 and total STAT6 in macrophages following 2-h treatment with HA and CD44 inhibitor at varying concentrations (n=3 for each group). (G) Western blotting analysis of p-STAT6 and total STAT6 in macrophages following 2-h treatment with HA and STAT6 inhibitor (AS1517499) at varying concentrations (n=4 for each group). (H) Schematic workflow: Conditioned medium from TGF-β1-stimulated NIH/3T3 fibroblasts was used to culture RAW264.7 macrophages for 24 h. Where indicated, RAW264.7 cells were co-treated with a CD44 inhibitor or a STAT6 inhibitor. Macrophage polarization was subsequently analyzed by flow cytometry. (I) Flow cytometry was used to measure the expression levels of CD206 (FITC) and CD86 (PE) (n=3 for each group). * P<0.05, ** P<0.01, *** P<0.001. HA, hyaluronic acid; FITC, fluorescein isothiocyanate; PE, phycoerythrin; p-, phosphorylated.

Article Snippet: Antibodies for Collagen type I α 1 chain (COL1A1; cat. no. 72026; 1:1,000), Phospho-STAT6 (Tyr641; cat. no. 56554S; 1:1,000) and α-smooth muscle actin (α-SMA; cat. no. 19245; 1:1,000) were obtained from Cell Signaling Technology, Inc.

Techniques: Flow Cytometry, Expressing, Enzyme-linked Immunosorbent Assay, Western Blot